PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) has restated and refiled its financial statements for the interim period ended June 30, 2025 (the “Amended Q2 2025 Statements”) as ...

A couple of Thursdays back, I was a minor (and I can’t emphasise enough the word ‘minor’) footnote in the tale of the ...

PHARMACORP RX INC. ("PharmaCorp" or the "Corporation") (TSXV: PCRX) has restated and refiled its financial statements for the interim period ...